Holen Sie sich die Stockscreener-App
3.60
1.41%
0.05
Handel nachbörslich:
3.56
-0.04
-1.11%
Veru Inc Aktie (VERU) Neueste Nachrichten
Raymond James Financial Cuts Veru (NASDAQ:VERU) Price Target to $20.00 - MarketBeat
Veru (NASDAQ:VERU) Issues Quarterly Earnings Results - MarketBeat
Is Veru Inc.’s ROE strong enoughMarket Activity Summary & Momentum Based Trading Signals - thegnnews.com
Veru (NASDAQ:VERU) Sets New 52-Week LowWhat's Next? - MarketBeat
Price Floor Holding on Veru Inc. — Rebound PossibleJuly 2025 Recap & Technical Entry and Exit Alerts - newsyoung.net
Veru Announces Novel Modified-Release Oral Formulation for Enobosarm - Yahoo Finance
Veru Inc. Charts Flash Early Recovery SignalsWeekly Volume Report & Low Risk High Win Rate Picks - newsyoung.net
Raymond James Keeps Their Buy Rating on Veru (VERU) - The Globe and Mail
Veru (STU:FMW0) Tariff Resilience Score : 5/10 (As of Aug. 14, 2025) - GuruFocus
Will Veru Inc. rebound enough to break evenQuarterly Profit Report & Fast Gain Swing Trade Alerts - Newser
Is Veru Inc. a strong growth stockMarket Volume Report & Short-Term Swing Trade Alerts - news-j.co.kr
What indicators show strength in Veru Inc.Options Play & Scalable Portfolio Growth Ideas - Newser
Why Veru Inc. stock attracts strong analyst attentionEarnings Beat & Safe Entry Zone Identification - Newser
Veru Inc. stock prediction for this weekMarket Risk Summary & Technical Buy Zone Confirmations - Newser
How sentiment analysis helps forecast Veru Inc.Trade Risk Summary & Weekly High Potential Stock Alerts - Newser
Top chart patterns to watch in Veru Inc.2025 Analyst Calls & Precise Buy Zone Tips - Newser
Is Veru Inc. meeting your algorithmic filter criteriaMarket Rally & Weekly Market Pulse Updates - Newser
Veru stock price target raised to $25 from $4 at Oppenheimer on GLP-1 muscle loss drug - Investing.com Australia
Raymond James Maintains Veru Inc(VERU.US) With Buy Rating, Raises Target Price to $20 - 富途牛牛
Anchoring Your Portfolio: Is VERU Stock a Safe Harbor? - investchronicle.com
VERU Stock: Analyst Maintains Outperform Rating, Lowers Price Ta - GuruFocus
Veru (FRA:FMW0) Tariff Resilience Score : 5/10 (As of Aug. 13, 2025) - GuruFocus
Veru stock price target lowered to $20 at Raymond James on obesity drug - Investing.com Nigeria
Statistical indicators supporting Veru Inc.’s strengthRecession Risk & Daily Profit Maximizing Tips - Newser
Veru Inc (VERU) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
Veru Inc. Reports Positive Results and Progress - TipRanks
Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress - GlobeNewswire
Full technical analysis of Veru Inc. stockTrade Ideas Based on Fundamental Metrics - Newser
Is Veru Inc. stock forming a triangle patternStocks with Highest Alpha - thegnnews.com
Veru Q3 2025 Earnings Call Transcript - MarketBeat
Transcript : Veru Inc., Q3 2025 Earnings Call, Aug 12, 2025 - MarketScreener
Veru's Q3 2025 Earnings Call: Unpacking Key Contradictions in Phase III Trial Costs and Enobosarm's Safety Profile - AInvest
VERU INC. SEC 10-Q Report - TradingView
Veru Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: Veru Inc. Q3 2025 sees significant EPS miss - Investing.com
Veru Inc. (NASDAQ:VERU) Looks Inexpensive After Falling 40% But Perhaps Not Attractive Enough - 富途牛牛
Why Investors Shouldn't Be Surprised By Veru Inc.'s (NASDAQ:VERU) 40% Share Price Plunge - simplywall.st
Veru Implements 1-for-10 Reverse Stock Split - TipRanks
Veru Inc. Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress - TradingView
Veru Inc. (VERU): A High-Risk, High-Reward Biotech Play with a Turnaround Story - AInvest
Evaluating Veru Inc. with trendline analysisFree Swing Setup With Technical Confirmation - Newser
Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru’s Enobosarm, Utilizing Laxxon’s SPID®-Technology - BioSpace
Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru's Enobosarm, Utilizing Laxxon's SPID®-Technology - Lelezard
Veru selects Laxxon’s SPID technology for modified-release enobosarm By Investing.com - Investing.com Nigeria
Veru selects Laxxon’s SPID technology for modified-release enobosarm - Investing.com
Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru’s Enobosarm, Utilizing Laxxon’s SPID®-Technology | FinancialContent - FinancialContent
Veru selects oral enobosarm formulation for development - The Pharma Letter
Veru Selects Novel Oral Formulation for Chronic Weight Loss Management Drug - MarketScreener
Veru selects modified release formulation for enobosarm weight drug - Investing.com
Veru selects modified release formulation for enobosarm weight drug By Investing.com - Investing.com UK
Veru Announces Selection of Novel Modified Release Oral - GlobeNewswire
Veru's New Weight Loss Drug Formulation Shows Promise with Extended Patent Protection Until 2046 - Stock Titan
0.94%
1.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):